Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+3.67%
+1.24%
-5.00%
+24.42%
MRNA
Moderna
$27.46
Chart
$27.22 (+0.88%)
$34.3 (-19.94%)
$40.72 (-32.56%)
$133.4 (-79.42%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.67%
+1.24%
-5.00%
+24.42%
MRNA
Moderna
Current Price
$27.46
Login to view Moderna (MRNA) recommendation from the last 90 days from financial news and social media.
Chart
$27.22 (+0.88%)
$34.3 (-19.94%)
$40.72 (-32.56%)
$133.4 (-79.42%)
MRNA Latest Headlines
Notable Thursday Option Activity: MRNA FDX LNG. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Moderna Inc (Symbol: MRNA) where a total volume of 57437 contracts has been traded thus far today a contract volume which is representative of approximately 5
Thu Jun 5, 2025
Moderna Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript.
Thu Jun 5, 2025
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case. The United States Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’.s finding of noninfringement in favor of ) in its ongoing patent battle with ) over mRNA-based including its Spikevax COVID-19 vaccine.The court held that Alnylam had acted as its lexicographer in defining the term “.branched alkyl”. in its patent specifications. That definition was included in Alnylam’.s infring
Thu Jun 5, 2025
FDA grants limited approval to Modernas new mRNA COVID vaccine.
Tue Jun 3, 2025
This Is What Whales Are Betting On Moderna. Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:) revealed 20 unusual trades.Delving into the details we found 40% of traders were ish while 45% showed bearish tendencies. Out of all the trades we spotted 4 were puts with a value of $317887 and 16 were calls valued at $3451522.Analyzing the Volume and Open Interest in these contracts it seems that the big players have been eyeing a p
Tue Jun 3, 2025
Brad Miller Joins Keystone as President of CoreAI. Former Moderna CIO and long-time Keystone partner to lead CoreAI as company scales enterprise adoption of AI-driven decision systems SEATTLE June 2 2025 /PRNewswire/ -- Keystone.ai a technology and services firm specializing in enterprise AI economics and technology advisory today...
Mon Jun 2, 2025
Modernas New COVID Vaccine Secures FDA-Clearance For Seniors At-Risk Individuals. The United States Food and Drug Administration (FDA) on Saturday approved ) mNexspike(mRNA-1283) a new vaccine against COVID-19 for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease .“.The FDA approval of our third product mNEXSPIKE….”. said .The FDA’.s approval of mNEXSPIKE is based on results from a r
Mon Jun 2, 2025
Modernas New COVID Vaccine Secures FDA-Clearance For Seniors At-Risk Individuals. The United States Food and Drug Administration (FDA) on Saturday approved ) mNexspike(mRNA-1283) a new vaccine against COVID-19 for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease .“.The FDA approval of our third product mNEXSPIKE….”. said .The FDA’.s approval of mNEXSPIKE is based on results from a r
Mon Jun 2, 2025
Modernas New COVID Vaccine Secures FDA-Clearance For Seniors At-Risk Individuals. The United States Food and Drug Administration (FDA) on Saturday approved ) mNexspike(mRNA-1283) a new vaccine against COVID-19 for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease .“.The FDA approval of our third product mNEXSPIKE….”. said .The FDA’.s approval of mNEXSPIKE is based on results from a r
Mon Jun 2, 2025
Moderna gains as FDA nod for next-gen COVID-19 vaccine.
Mon Jun 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MRNA Stock trends
MRNA Stock performance
MRNA Stock analysis
MRNA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
